Welcome to the Fifthteenth Annual Health Law and Policy Summer Institute!
Courses Offered:
HEALTH CARE BUSINESS TRANSACTIONS (LAW-719-008)
1 academic credit
Fridays, June 4 and 18 (11:00 am - 4:00 pm ET)
In addition to the live class time, academic credit students will be required to independently complete 3 hours of additional asynchronous material.
Lecturer: Ms. Julia Reiland
This course is designed to introduce students to the business and legal issues that arise in health care transactions and the complex regulatory environment surrounding such transactions. This course will cover health care mergers & acquisitions, joint ventures, and contracting with providers, suppliers, and vendors. Students will gain practical knowledge and an opportunity to participate in health care contract drafting, issue spotting, and negotiation exercises. The goal is to provide substantial instruction in professional and experiential skills, including practical experience in negotiating and drafting health care deal documents. In addition to lectures that cover basic legal concepts, students will engage in experiential group activities similar to that of a transactional lawyer. These exercises will help develop a student’s ability to apply legal analysis to real client scenarios and develop written and oral communication skills. Because this course is intended to develop a student’s practical skill set, exercises will also focus on a student’s ability to evaluate how legal analysis impacts business expectations.
DIGITAL HEALTH & THE LAW: ARTIFICIAL INTELLIGENCE & TELEHEALTH APPLICATIONS (LAW 719HT-001)
1 academic credit
Saturdays, June 11 & 25 (11:00 am - 4:00 pm ET)
In addition to the live class time, academic credit students will be required to independently complete 3 hours of additional asynchronous material.
Lecturer: Ms. Stephanie WillisThis course will explore the latest legal developments in the United States pertaining to the use of technology to deliver or support healthcare delivery, with a focus on telehealth/remote patient monitoring and artificial intelligence. The laws and regulations governing these technologies are evolving rapidly, especially because of the increasing use of and investment in them in response to the global COVID-19 pandemic. During this course, students will learn about the laws and regulations that federal and state agencies use to create licensing, reimbursement, liability, and privacy protection frameworks that can advance or pose barriers to telehealth/remote patient monitoring and AI technologies. Students will be expected to understand these legal frameworks and examine how the regulation of digital health technologies must balance complex societal goals such as access, innovation, equity, cost-effectiveness, and safety through the course’s readings, group discussions, and written responses to hypotheticals.
Pharmaceuticals and the Law (LAW-719JJ-001)
1 academic credit
Sundays, June 5 & 12 (11:00 am - 4:00 pm ET)
In addition to the live class time, academic credit students will be required to independently complete 3 hours of additional asynchronous material.
Lecturer: Ms. Sonali Gunawardhana
This course will introduce students to the broad range of legal and policy issues that impact the biopharmaceutical industry in the United States. Through reading materials, lectures and discussions, students will explore the complex regulatory framework governing pharmaceutical innovation and patient access to new therapies. Emphasis will be placed on students learning about drug pricing and regulation of drug plan financing (including pharmacy benefit management and rebate regulation) and the regulation of drug and biologic development, approval, and promotion. Additional topics that will be covered include: (i) fraud and abuse laws and regulations and "transparency" policy trends, including disclosure of and restrictions on interactions with healthcare providers; (ii) healthcare reform policy trends; (iii) statutory intellectual property protections for biopharmaceuticals; (iv) First Amendment issues arising in the regulation of various pharmaceutical industry activities; and (v) the interplay between biopharm regulation and product liability.